{
    "clinical_study": {
        "@rank": "107738", 
        "arm_group": [
            {
                "arm_group_label": "Hexa Lot A Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive 3 doses of Infanrix hexa (lot A) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. Subjects will receive a booster dose of Infanrix and Hiberix vaccines at 15-18 months of age"
            }, 
            {
                "arm_group_label": "Hexa Lot B Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive 3 doses of Infanrix hexa (lot B) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. Subjects will receive a booster dose of Infanrix and Hiberix vaccines at 15-18 months of age"
            }, 
            {
                "arm_group_label": "Hexa Lot C Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive 3 doses of Infanrix hexa (lot C) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. Subjects will receive a booster dose of Infanrix and Hiberix vaccines at 15-18 months of age"
            }, 
            {
                "arm_group_label": "Pedia Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. Subjects will receive a booster dose of Infanrix and ActHIB vaccines at 15-18 months of age"
            }, 
            {
                "arm_group_label": "Penta Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects in this group will receive 3 doses of Pentacel and Engerix-B* co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. *Subjects in the Penta Group who have received a dose of hepatitis B vaccine from birth up to 30 days prior to study vaccination should not receive Engerix-B at 4 months of age (Visit 2). Subjects will receive a booster dose of Pentacel vaccine at 15-18 months of age."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals'\n      Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4\n      and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK\n      Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age."
        }, 
        "brief_title": "Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Poliomyelitis", 
            "Diphtheria", 
            "Haemophilus Influenzae Type b", 
            "Tetanus", 
            "Acellular Pertussis", 
            "Hepatitis B"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diphtheria", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Influenza, Human", 
                "Whooping Cough", 
                "Poliomyelitis", 
                "Tetanus"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects' parent(s)/ LAR(s) who, in the opinion of the investigator, can and will\n             comply, with the requirements of the protocol.\n\n          -  A male or female between, and including, 6 and 12 weeks of age at the time of the\n             first vaccination.\n\n          -  Born full-term (i.e. after a gestation period of 37 weeks to less than 42 completed\n             weeks [259 to 293 days]).\n\n          -  Written informed consent obtained from parent(s)/LAR(s) of the subject.\n\n          -  Healthy subjects as established by medical history and clinical examination before\n             entering into the study.\n\n          -  Infants who have not received a previous dose of hepatitis B vaccine or those who\n             have received only 1 dose of hepatitis B vaccine administered at least 30 days prior\n             to enrolment.\n\n        Exclusion Criteria:\n\n          -  Child in care\n\n          -  Use of any investigational or non-registered product (drug or vaccine) other than the\n             study vaccines within 30 days preceding the first dose of study vaccines, or planned\n             use during the study period.\n\n          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants\n             or other immune-modifying drugs since birth. For corticosteroids, this will mean\n             prednisone \u2265 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.\n\n          -  Planned administration/administration of a vaccine not foreseen by the study protocol\n             within the period starting from 30 days before the first vaccination until 30 days\n             after Dose 3 (Epoch 001, primary vaccination) and from 30 days before the booster\n             Dose 4 until 30 days after booster Dose 4 (Epoch 002, booster vaccination), i.e. the\n             end of the study:\n\n               -  Inactivated influenza and hepatitis A vaccines are allowed throughout the study.\n\n               -  Routine administration(s) of vaccines are allowed from 30 days after the last\n                  dose of primary vaccination until 30 days before the booster dose and after\n                  post-booster blood sampling. Routine administration of measles-mumps-rubella\n                  vaccine, varicella, pneumococcal vaccines are allowed from 30 days after last\n                  dose of primary vaccine until 30 days before booster dose and from post-booster\n                  blood sampling, as well as according to the recommended immunization schedule in\n                  US.\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational product (pharmaceutical product or device).\n\n          -  History of Hib, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus\n             and hepatitis B diseases.\n\n          -  Previous vaccination against Hib, diphtheria, tetanus, pertussis, pneumococcus,\n             rotavirus and/or poliovirus; more than one previous dose of hepatitis B vaccine.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination (no laboratory testing required).\n\n          -  Family history of congenital or hereditary immunodeficiency.\n\n          -  History of any reaction or hypersensitivity likely to be exacerbated by any component\n             of the vaccines (including yeast).\n\n          -  Hypersensitivity to latex.\n\n          -  Major congenital defects or serious chronic illness.\n\n          -  History of any neurological disorders including seizures.\n\n          -  Administration of immunoglobulins and/or any blood products since birth or planned\n             administration during the study period.\n\n          -  History of intussusception or of any uncorrected congenital malformation of the\n             gastrointestinal tract that would predispose the infant to intussusception.\n\n          -  History of Severe Combined Immunodeficiency Disease (SCID).\n\n          -  Acute disease and/or fever at the time of enrolment.\n\n               -  Fever is defined as temperature \u226538.0\u00b0C /100.4\u00b0F by any route. The preferred\n                  route for recording temperature in this study will be rectal for Epoch 001 and\n                  axillary for Epoch 002.\n\n               -  Subjects with a minor illness (such as mild diarrhea, mild upper respiratory\n                  infection) without fever may, be enrolled at the discretion of the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Weeks", 
            "minimum_age": "6 Weeks"
        }, 
        "enrollment": {
            "#text": "585", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096263", 
            "org_study_id": "117119"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Hexa Lot B Group", 
                    "Hexa Lot A Group", 
                    "Hexa Lot C Group"
                ], 
                "description": "3 doses administered intramuscularly in the right thigh.", 
                "intervention_name": "Infanrix hexa", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Pedia Group", 
                "description": "3 doses administered intramuscularly in the right thigh", 
                "intervention_name": "Pediarix", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Pedia Group", 
                "description": "4 doses administered intramuscularly in the upper left thigh", 
                "intervention_name": "ActHIB", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Penta Group", 
                "description": "4 doses administered intramuscularly in the right thigh", 
                "intervention_name": "Pentacel", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Penta Group", 
                "description": "2 or 3 doses administered intramuscularly in the upper left thigh", 
                "intervention_name": "Engerix-B", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Pedia Group", 
                    "Hexa Lot B Group", 
                    "Hexa Lot A Group", 
                    "Hexa Lot C Group"
                ], 
                "description": "1 dose administered intramuscularly in the right thigh", 
                "intervention_name": "Infanrix", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Hexa Lot B Group", 
                    "Hexa Lot A Group", 
                    "Hexa Lot C Group"
                ], 
                "description": "1 dose administered intramuscularly in the left thigh", 
                "intervention_name": "Hiberix", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Penta Group", 
                    "Pedia Group", 
                    "Hexa Lot B Group", 
                    "Hexa Lot A Group", 
                    "Hexa Lot C Group"
                ], 
                "description": "3 doses administered intramuscularly in the lower left thigh", 
                "intervention_name": "Prevnar13", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Penta Group", 
                    "Pedia Group", 
                    "Hexa Lot B Group", 
                    "Hexa Lot A Group", 
                    "Hexa Lot C Group"
                ], 
                "description": "2 doses administered orally", 
                "intervention_name": "Rotarix", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Infants", 
            "Safety", 
            "Healthy", 
            "Infanrix Hexa", 
            "Immunogenicity"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85741"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72703"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92804"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Daly City", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94015"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93726"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Hayward", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94545"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94611"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Pleasanton", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94588"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Roseville", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95661"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95815"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95823"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "San Jose", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95119"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Clara", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95051"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Walnut Creek", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94596"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Colorado Springs", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80922"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Altamonte Springs", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32701"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Orange City", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32763"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Marietta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30062"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Woodstock", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30189"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Nampa", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83686"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67010"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Newton", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67114"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Topeka", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66604"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67205"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40291"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Nicholasville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40356"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21045"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45414"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Erie", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16505"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Sellersville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "18960"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Kingsport", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37660"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Layton", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84041"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Payson", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84651"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Provo", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84604"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84109"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "South Jordon", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84095"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "St. George", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84790"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "West Jordan", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84088"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22902"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Ellensburg", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98926"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "Immunogenicity and Safety Study of GSK Biologicals' Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Anti-PT, anti-FHA, anti-PRN antibody concentrations.", 
            "measure": "Evaluation of immunogenicity with respect to pertussis components of the study vaccines Infanrix hexa and Pediarix", 
            "safety_issue": "No", 
            "time_frame": "1 month after the third dose of the primary vaccination (Month 7)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096263"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Anti-PT, anti-FHA, anti-PRN seropositivity status", 
                "measure": "Evaluation of immunogenicity (other parameters) with respect to the pertussis component of the study vaccines Infanrix hexa, Pentacel and Pediarix", 
                "safety_issue": "No", 
                "time_frame": "1 month after the third dose of the primary vaccination (Month 7)"
            }, 
            {
                "description": "Anti-PT, anti-FHA, anti-PRN antibody concentrations", 
                "measure": "Evaluation of immunogenicity (other parameters) with respect to the pertussis component of the study vaccine Pentacel", 
                "safety_issue": "No", 
                "time_frame": "1 month after the third dose of the primary vaccination (Month 7)"
            }, 
            {
                "description": "Anti-D, anti-T, anti-HBs, anti-poliovirus types 1, 2 and 3 and anti-PRP seroprotection status, anti-PRP antibody concentrations \u22651.0 \u00b5g/mL and antibody concentrations/titers", 
                "measure": "Evaluation of immunogenicity with respect to the other components of the study vaccines Infanrix hexa, Pediarix, ActHIB, Pentacel and Engerix-B", 
                "safety_issue": "No", 
                "time_frame": "1 month after the third dose of the primary vaccination (Month 7)"
            }, 
            {
                "description": "\u2012 Occurrence of each solicited local symptom (any, \u2265Grade 2, Grade 3 and symptoms requiring medical attention) (Infanrix hexa, Pediarix, ActHIB, Pentacel and Engerix-B) \u2012 Occurrence of each solicited general symptom (any, \u2265Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related)", 
                "measure": "Occurrence of solicited local and general symptoms", 
                "safety_issue": "No", 
                "time_frame": "Within 4 days (Day 0 - Day 3) after each vaccination"
            }, 
            {
                "measure": "Occurrence of unsolicited adverse events", 
                "safety_issue": "No", 
                "time_frame": "Within 31 days (Day 0 - Day 30) after each vaccination"
            }, 
            {
                "description": "Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies)", 
                "measure": "Occurrence of specific adverse events", 
                "safety_issue": "No", 
                "time_frame": "From Day 0 up to 6 months post primary vaccination"
            }, 
            {
                "measure": "Occurrence of Serious adverse events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "From Day 0 up to 6 months post primary vaccination"
            }, 
            {
                "description": "Anti-D, anti-T, anti- PT, anti-FHA and anti-PRN, anti-HBs, anti-PRP and anti-poliovirus 1, 2, 3 seroprotection/ seropositivity status, anti-PRP antibody concentrations \u22651 \u00b5g/mL and antibody concentrations/ titers", 
                "measure": "Immunogenicity with respect to all study vaccines in terms of antibody concentration and titres", 
                "safety_issue": "No", 
                "time_frame": "Before the booster dose (Dose 4) (Study month 13-16)"
            }, 
            {
                "description": "\u2012\tAnti-D, anti-T, anti- PT, anti-FHA and anti-PRN, anti-PRP seroprotection/ seropositivity status and antibody concentrations. - Anti-PT, anti-FHA and anti-PRN booster response. - Anti-PRP antibody concentrations \u22651 \u00b5g/mL. - Anti-D and anti-T antibody concentrations \u22651 IU/mL", 
                "measure": "Immunogenicity with respect to the study vaccine Pentacel", 
                "safety_issue": "No", 
                "time_frame": "1 month after the booster dose (Dose 4) (Study month 14-17)"
            }, 
            {
                "description": "\u2012 Anti-D, anti-T, anti- PT, anti-FHA and anti-PRN seroprotection/ seropositivity status and antibody concentrations. - Anti-PT, anti-FHA and anti-PRN booster response. - Anti-D and anti-T antibody concentrations \u22651 IU/mL", 
                "measure": "Immunogenicity with respect to the study vaccine Infanrix", 
                "safety_issue": "No", 
                "time_frame": "1 month after the booster dose (Dose 4) (Study month 14-17)"
            }, 
            {
                "description": "\u2012 Anti-PRP seroprotection status and antibody concentrations.\u2012 Anti-PRP antibody concentrations \u22651 \u00b5g/mL", 
                "measure": "Immunogenicity with respect to the study vaccines ActHIB and Hiberix", 
                "safety_issue": "No", 
                "time_frame": "1 month after the booster dose (Dose 4) (Study month 14-17)"
            }, 
            {
                "description": "\u2012 Occurrence of each solicited local symptom (any, \u2265Grade 2, Grade 3 and symptoms requiring medical attention). - Occurrence of each solicited general symptom (any, \u2265Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related).", 
                "measure": "Occurence of solicited local and general symptoms", 
                "safety_issue": "No", 
                "time_frame": "Within 4 days (Day 0 - Day 3) after booster vaccination (Infanrix, Hiberix, ActHIB and Pentacel)"
            }, 
            {
                "measure": "Occurence of unsolicited adverse events", 
                "safety_issue": "No", 
                "time_frame": "Within 31 days (Day 0 - Day 30) after booster vaccination"
            }, 
            {
                "description": "Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies)", 
                "measure": "Occurence of specific adverse events", 
                "safety_issue": "No", 
                "time_frame": "From the booster dose (Study month 13-16) up to 1 month after the booster vaccination (Study month 14-17)"
            }, 
            {
                "measure": "Occurrence of SAEs", 
                "safety_issue": "No", 
                "time_frame": "From the booster dose (Study month 13-16) up to 1 month after the booster vaccination (Study month 14-17)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}